医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Presbia to Participate in the 2015 Australasian Society of Cataract and Refractive Surgeons Conference

2015年09月24日 PM09:00
このエントリーをはてなブックマークに追加


 

DUBLIN

Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration will be attending the 19th Annual Australasian Society of Cataract and Refractive Surgeons (AUSCRS) Conference being held from October 7th through the 10th at Outrigger Conference Centre in Noosa, Queensland, Australia. Presbia representatives, including President and CEO Todd Cooper and Vice President of Sales John Strobel, will be at the meeting to discuss the Presbia Flexivue Microlens™ with AUSCRS members, leaders in the field of ophthalmology. The Presbia Flexivue Microlens is a corneal inlay solution for presbyopia, the age-related loss of near-vision.

“Australia, New Zealand and South Korea are key markets for Presbia and we are very pleased that we will have the opportunity at the conference to expand the awareness of AUSCRS members of the Presbia Flexivue MicrolensTM as safe, effective and the best surgical treatment for presbyopia,” said Todd Cooper. “This meeting will accelerate our expansion into these key countries and educate surgeons on the benefits of our surgical solution to reduce the need for reading glasses.”

Presbia representatives will be available to meet with surgeons during the conference at Presbia’s booth #11 to discuss Presbia’s products and procedures.

Forward-Looking Statements

Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.

About Presbia

Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens commenced in 2014.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150924005264/en/

CONTACT

Presbia PLC
Monica Yamada, 323-860-4903
monica@presbia.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent